Successful Crizotinib-Targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma
preprint
OA: closed
Abstract
Anaplastic lymphoma kinase ( ALK )-fusion sarcomas are rare, part of the emerging theoretically-targetable tyrosine-kinase RAS::MAPK -pathway fusion myopericytic-ovoid-sarcomas. We report our clinicopathologic and treatment experience with an ALK -fusion sarcoma. A novel ERC1-unaligned- ALK-fusion infiltrative nonmetastatic low-grade sarcoma of the right hand of a 15-month-old male was treated with crizotinib, an ALK tyrosine-kinase inhibitor as oral monotherapy, inducing complete radiographic and clinical resolution by 10 months and sustained response now 8 months after elective discontinuation. Crizotinib can successfully be used to treat unresectable novel ALK -fusion sarcomas.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00